Open Forum Infectious Diseases
Large clinical trials on drugs for hospitalized COVID-19 patients have shown significant effects on mortality. There may be a discrepancy with the observed real-world effect. We describe the clinical characteristics and outcomes of hospitalized COVID-19 patients in the Netherlands during four pandemic waves, and analyze the association of the newly introduced treatments with mortality, ICU-admission, and discharge alive.
We conducted a nationwide retrospective analysis of hospitalized COVID-19 patients between 27 February 2020 and 31 December 2021. Patients were categorized into waves and into treatment groups (hydroxychloroquine, remdesivir, neutralizing SARS-CoV-2 mAb, corticosteroids, and IL-6 antagonists). Four types of Cox-regression analyses were used: unadjusted, adjusted, propensity matched, and propensity weighted.
Among 5643 patients from 11 hospitals we observed a changing epidemiology during four pandemic waves, with a decrease in median age (67 to 64 years, p < 0.001), in in-hospital mortality on the ward (21% to 15%, p < 0.001), and a trend on the ICU (24% to 16%, p = 0.148). In ward patients, hydroxychloroquine was associated with increased mortality (1.54 (95% CI 1.22-1.96)); remdesivir with a higher rate of discharge alive within 29 days (1.16 (95% CI 1.03-1.31)). Corticosteroids were associated with a decrease in mortality (0.82 (95% CI 0.69-0.96); the results of IL-6 antagonists were inconclusive. In patients directly admitted to the ICU, hydroxychloroquine, corticosteroids, and IL-6 antagonists were not associated with decreased mortality.
Both remdesivir and corticosteroids were associated with better outcomes in ward patients with COVID-19. Continuous evaluation of real-world treatment effects is needed.
Read full article here
Click this link for the original source of this article.
Author: covid 19 updates
This content is courtesy of, and owned and copyrighted by, https://covid19updates.org and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.